Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
macular edema
Biotech
Roche heads to FDA as eye disease trials yield mixed data
Roche is forging ahead with plans to seek approval for an eye disease candidate despite missing the primary endpoint in one of its phase 3 trials.
Nick Paul Taylor
Oct 20, 2025 9:28am
Kodiak asset matches Regeneron's Eylea in macular edema phase 3
Aug 8, 2022 9:53am
After axing leading program, Unity now cuts staff
Sep 16, 2020 7:35am
Regeneron scraps Eylea combination after phase 2 setbacks
Nov 27, 2017 6:39am
Japanese robotics company Riverfield bags $10M and more—News of Note
Oct 30, 2017 11:50am
